Listen to Dr. Brett McQueen, who directs the Center for Pharmaceutical Value at the University of Colorado Anschutz Medical Campus in Denver, discuss issues important to payers around the use of screening for T1 diabetes and the first therapy to slow the progression from stage 2 to stage 3 diabetes.

Listen to Dr. Brett McQueen, who directs the Center for Pharmaceutical Value at the University of Colorado Anschutz Medical Campus in Denver, discuss issues important to payers around the use of screening for T1 diabetes and the first therapy to slow the progression from stage 2 to stage 3 diabetes.

Listen to Dr. Brett McQueen, who directs the Center for Pharmaceutical Value at the University of Colorado Anschutz Medical Campus in Denver, discuss issues important to payers around the use of screening for T1 diabetes and the first therapy to slow the progression from stage 2 to stage 3 diabetes.
&nbsp;

The Economic Implications of Screening for Type 1 Diabetes

The DETECT T1D initiative is aiming to provide clinicians and patients with information on the screening and early detection of T1D, as well as therapeutic advances to delay disease progression. The development of therapies to delay progression to clinical T1D has the potential to alter paradigms of care, and with it there is an emphasis on screening, early detection, multidisciplinary care, and patient education to help bring these advances to practice.

Share The Economic Implications of Screening for Type 1 Diabetes

Sign up to save your podcasts

The Economic Implications of Screening for Type 1 Diabetes

The Economic Implications of Screening for Type 1 Diabetes